Topical Calcineurin Inhibitors

Patricia Tinio; Mark G. Lebwohl

doi:10.1201/b14276-12

Topical Calcineurin Inhibitors

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

The calcineurin inhibitors were developed as an alternative to topical and systemic glucocorticoids for immunosuppressive therapy. They were primarily used for the prevention of organ transplant rejection. These drugs include cyclosporin and the macrolides tacrolimus (FK 506) and, most recently, pimecrolimus (SDZ ASM 981), which are known to modify immune function by inhibition of calcineurin-dependent reactions critical in the production of inflammatory cytokines (1).

Original language	English
Title of host publication	Mild-to-Moderate
Subtitle of host publication	Psoriasis
Publisher	CRC Press
Pages	105-113
Number of pages	9
ISBN (Electronic)	9781420019315
ISBN (Print)	9780849337239
DOIs	https://doi.org/10.1201/b14276-12
State	Published - 1 Jan 2006

Access to Document

10.1201/b14276-12

Cite this

@inbook{21cda98afa464375bf47d656dca3cc0a,

title = "Topical Calcineurin Inhibitors",

abstract = "The calcineurin inhibitors were developed as an alternative to topical and systemic glucocorticoids for immunosuppressive therapy. They were primarily used for the prevention of organ transplant rejection. These drugs include cyclosporin and the macrolides tacrolimus (FK 506) and, most recently, pimecrolimus (SDZ ASM 981), which are known to modify immune function by inhibition of calcineurin-dependent reactions critical in the production of inflammatory cytokines (1).",

author = "Patricia Tinio and Lebwohl, {Mark G.}",

note = "Publisher Copyright: {\textcopyright} 2006 by Taylor and Francis Group, LLC.",

year = "2006",

month = jan,

day = "1",

doi = "10.1201/b14276-12",

language = "English",

isbn = "9780849337239",

pages = "105--113",

booktitle = "Mild-to-Moderate",

publisher = "CRC Press",

}

TY - CHAP

T1 - Topical Calcineurin Inhibitors

AU - Tinio, Patricia

AU - Lebwohl, Mark G.

PY - 2006/1/1

Y1 - 2006/1/1

N2 - The calcineurin inhibitors were developed as an alternative to topical and systemic glucocorticoids for immunosuppressive therapy. They were primarily used for the prevention of organ transplant rejection. These drugs include cyclosporin and the macrolides tacrolimus (FK 506) and, most recently, pimecrolimus (SDZ ASM 981), which are known to modify immune function by inhibition of calcineurin-dependent reactions critical in the production of inflammatory cytokines (1).

AB - The calcineurin inhibitors were developed as an alternative to topical and systemic glucocorticoids for immunosuppressive therapy. They were primarily used for the prevention of organ transplant rejection. These drugs include cyclosporin and the macrolides tacrolimus (FK 506) and, most recently, pimecrolimus (SDZ ASM 981), which are known to modify immune function by inhibition of calcineurin-dependent reactions critical in the production of inflammatory cytokines (1).

UR - http://www.scopus.com/inward/record.url?scp=85152846206&partnerID=8YFLogxK

U2 - 10.1201/b14276-12

DO - 10.1201/b14276-12

M3 - Chapter

AN - SCOPUS:85152846206

SN - 9780849337239

SP - 105

EP - 113

BT - Mild-to-Moderate

PB - CRC Press

ER -

Topical Calcineurin Inhibitors

Abstract

Access to Document

Fingerprint

Cite this